bioRxiv · 10.1101/2021.02.16.431305
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Abstract
We generated several versions of the receptor binding domain (RBD) of the Spike protein with mutations existing within newly emerging variants from South Africa and Brazil. We found that the mutant RBD with K417N, E484K, and N501Y exchanges has higher binding affinity to the human receptor compared to the wildtype RBD. This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S., Reynoso, L., Downey, G., Frankel, S., Kappler, J., Marrack, P., Zhang, G.. 2021-02-16. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. https://doi.org/10.1101/2021.02.16.431305
Cite the original work for its findings. Save a collection to share your selection of sources.